suggest that clinical isolates containing embB 306 mutations with MICs overlapping the critical concentration are associated with discordant ethambutol susceptibility test results. The clinical significance of borderline resistance in combination treatment of tuberculosis remains to be determined before alternative ethambutol breakpoints are considered.
Ethambutol (EMB) inhibits arabinogalactan synthesis and resistance to EMB is associated with mutations in three genes involved in arabinogalactan synthesis termed emb CAB [1] . These genes are organized as a 10-kbp operon, designated the EMB-resistance-determining region [1] . The most frequent point mutations associated with EMB resistance occur at codon 306 in the embB gene ( embB 306) [1] [2] [3] . Single nucleotide polymorphisms (SNPs) described in this codon are ATG ] GTG, CTG, ATA, ATC and ATT, resulting in three amino acid substitutions methionine (M) (ATG) ] valine (V) (GTG), leucine (L) (CTG) and isoleucine (I) (ATA; ATC; ATT) [1, 3] . Allelic exchange experiments demonstrated that mutations at emb B306 are associated with decreased sus-
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TM TB System and correlated with the genotypic test results. These data were analyzed to find information that could be used to clarify discordant ethambutol susceptibility test results. Results: Mutations M306I (n = 56), M306V (n = 18) and M306L (n = 3) in M. tuberculosis showed decreased susceptibility to ethambutol. The minimum inhibitory concentrations (MICs) in 73% (56/77) of embB 306 mutants were at or just above the critical concentration (MICs, 5.0 to ^ 12.5 g/ml) of ethambutol reflecting borderline (or intermediate) resistance. Eight ethambutol-resistant isolates lacked embB mutations, probably due to mutational alterations elsewhere in the genome. Conclusion: Our findings ceptibility to EMB [2] [3] [4] . Sequence variation in embB 306 has therefore been proposed as a promising molecular marker to predict EMB resistance in Mycobacterium tuberculosis [2] . However, reports that mutations in embB 306 were also present in EMB-susceptible strains question the reliability of this mutation as a reliable marker of resistance [5, 6] .
Disparity in phenotypic susceptibility results of EMB has widely been reported and various reasons have been linked to poor reproducibility [1, 7, 8] . Among these are methodological variations, heteroresistance, and the likelihood that the narrow range between the minimum inhibitory concentrations (MICs) of wild-type and resistant isolates give rise to borderline results [2, [7] [8] [9] .
The aim of this study was (1) to correlate mutations in the embB gene at codon 306 with the MIC levels of EMB in clinical isolates of M. tuberculosis and (2) to analyze the quantitative resistance and molecular data to clarify inconsistencies in routine EMB susceptibility test results.
Materials and Methods
A total of 111 drug-resistant M. tuberculosis clinical isolates were selected for study. The isolates were obtained from separate patients resident in the Western Cape, South Africa. Aliquots of stock cultures were prepared and kept under cryogenic conditions (-80 ° C). The resistance status of all isolates was confirmed by BACTEC TM 960 TM testing (Becton Dickinson Diagnostic Systems, Sparks, Md., USA) according to the standard critical concentrations set by the World Health Organization [10] . Fifty-two isolates were extensively drug-resistant (XDR), 47 were multidrug-resistant (MDR), 10 were resistant to both isoniazid (INH) plus streptomycin and two were resistant to INH. The genotypes of all selected isolates were previously determined and categorized as typical Beijing (n = 31), atypical Beijing (n = 49) [11] and Low Copy Clade (LCC; n = 31) strains [12] . Within the typical Beijing group were 8 XDR and 23 MDR strains; the atypical Beijing family was comprised of 30 XDR, 17 MDR and 2 INH monoresistant strains. The LCC included 14 XDR, 7 MDR and 10 isolates that were resistant to INH and streptomycin.
All the isolates were screened for SNPs in a 240-bp region of the embB gene, which encodes amino acids 271-350. This region was amplified by PCR with primer sets as previously described [13] : Emb151 (5 -CGGCATGCGCCGGCTGATTC-3) and EmbB131 (5 -TCCACAGACTGGCGTCGCTG-3). Amplicons were sequenced with an ABI PRISM DNA sequencer (Applied Biosystems, Foster City, Calif., USA) and the resulting chromatograms were analyzed by the use of Chromas software (Technelysium Pty Ltd).
The MICs for EMB were determined by quantitative drug susceptibility testing in BACTEC MGIT 960 eXtended individual Susceptibility Testing (TB eXiST) for EpiCenter TM V5.75A (BD Bioscience, Erembodegem, Belgium) as described [14] . EMB (Sigma-Aldrich, Kempton Park, South Africa) was prepared in sterile distilled water, filter-sterilized and stored at -80 ° C for up to 6 months. All isolates were subjected to quantitative drug susceptibility testing at EMB concentrations of 1.25, 2.5, 5.0, 12.5, 25.0 and 50.0 g/ml. The interpretation of MIC values was based on the 1% proportional method. A critical concentration of 5.0 g/ ml was used to distinguish between EMB-susceptible and EMBresistant isolates [10] . M. tuberculosis H37Rv (ATCC 27294) was included as a drug-susceptible reference strain for quality control purposes.
Results
The distribution of embB 306 mutations amongst 111 clinical isolates of three different genotypes, together with sequence and quantitative drug susceptibility data, is presented in tables 1 and 2 . Thirty-four (31%) of the 111 isolates lacked embB 306 mutations and 76% (26/34) of these exhibited EMB MICs of 1.25 to ^ 2.5 g/ml, which are below the standard critical concentration of 5.0 g/ ml [10] ( tables 1 , 2 ). The susceptibility levels of these isolates were similar to those displayed by the susceptible M. tuberculosis reference strain (H37Rv) confirming that they are genotypically and phenotypically susceptible to EMB. The 26 isolates were identified to be of the typical Beijing (n = 6), atypical Beijing (n = 4) and LCC (n = 16) genotypes. Amongst the 26 isolates were 2 XDR, 12 MDR, 2 INH monoresistant and 10 INH plus streptomycin-resistant strains. Eight of the 34 isolates that had no embB mutations showed phenotypic resistance to EMB exhibiting MICs of 1 5.0 to ^ 12.5 g/ml (n = 1), 1 12.5 to ^ 25.0 g/ml (n = 6) and 1 25.0 to ^ 50.0 g/ml (n = 1). All 8 isolates were typical Beijing strains and 4 were MDR and 4 XDR.
In comparison, 69% (77/111) of the test isolates had SNPs at embB 306 with 4 different nucleotide substitutions (ATG ] ATC, ATA, GTG and CTG) associated with decreased susceptibility to EMB. M306I substitutions occurred as a result of nucleotide alterations at ATG ] ATC (n = 32) and ATG ] ATA (n = 24) in 56/77 (73%) isolates. Eighteen (23%) of the 77 isolates contained an M306V (ATG ] GTG) mutation and 3/77 (4%) had an M306L (ATG ] CTG) replacement ( table 1 ) . Among the 77 mutant isolates, 67 (87%) were phenotypic resistant and 10 (13%) phenotypic susceptible to EMB as per critical concentration testing [10] . The EMB MIC of the 10 isolates was equivalent to the critical concentration (5.0 g/ml) and 2-to 4-fold higher than those of the 26 susceptible wild-type isolates. Within the typical Beijing family 55% (17/31) had embB 306 mutations, dominated by M306V (88%; 15/17). Thirteen (87%; 13/15) M306V mutants had EMB MICs of 1 12.5 to ^ 25.0 g/ml and 2/15 exhibited MICs of 1 5.0 to ^ 12.5 g/ml and 1 25 to ^ 50 g/ml, respectively. Only 2/17 M306I mutations were detected among the typical Beijing isolates; one of them had an MIC of 1 5.0 to ^ 12.5 g/ml and the other one showed an MIC of 1 12.5 to ^ 25.0 g/ml. Among the atypical Beijing isolates, 92% (45/49) had SNPs in embB 306 and of these 91% (41/45) possessed the M306I mutations, ATC (n = 23) and ATA (n = 18). The EMB MICs in 38/41 (93%) of these isolates were 5.0 to ^ 12.5 g/ml reflecting lowlevel or intermediate resistance. Higher MICs ( 1 12.5 to ^ 25.0 g/ml) were demonstrated in only 3/41 (7%) of the atypical Beijing isolates with the M306I substitution (ATG ] ATC). The other four isolates within this genotype had M306V (n = 1) and M306L (n = 3) mutations with EMB MICs of 1 5.0 to ^ 12.5 and 1 12.5 to ^ 25 g/ ml, respectively. embB 306 mutations were detected in 48% (15/31) of the LCC isolates and 87% (13/15) of these harbored the M306I mutation, while the amino acid substitution M306V was present in 2/13 of the isolates. All 15 LCC mutant isolates exhibited EMB MICs (5.0 to ^ 12.5) similar to those observed in most of the atypical Beijing strains. 
Discussion
Amongst the 56 isolates with M306I substitutions, 93% (52/56) had MICs equal or moderately above the critical concentration (MICs, 5.0 to ^ 12.5 g/ml). We suggest that these borderline results account for the discordance found among isolates that were genotypic resistant but phenotypic susceptible. This problem can be reduced by adjusting the current critical concentration or by introducing two or multiple breakpoints, based on measures of quantitative drug susceptibility and genotypic testing. A susceptibility breakpoint of 4.0 g/ml for EMB has recently been suggested [15] . This recommendation was based on a pharmacokinetic (PK) and pharmacodynamic (PD) approach, but it failed to specify the relevant in vitro conditions for susceptibility testing for which this breakpoint is suitable [15] . Using a reduced breakpoint to detect phenotypic resistance should improve the detection rate of mutants that confer low-level resistance to EMB. It is, however, important to introduce an assessment scheme that identifies intermediate susceptible strains, based on the MIC distribution of EMB. Patients with moderately increased MICs may still benefit from treatment, especially in situations where therapeutic options are limited, since low-level (borderline) resistance does not necessarily imply clinical resistance.
EMB has a rather narrow therapeutic index as a result of ocular toxicity which is dose-related [16] . The standard recommended daily doses of EMB for adults are 15-20 mg/kg body weight daily, or 3 times weekly at 25-35 mg/ kg body weight [16] . A peak serum level of 5.0 g/ml is achieved following a dose of 25 mg/kg of EMB [16] , which is equivalent to the MICs of low-level (or borderline) EMB-resistant isolates. EMB serum concentrations are dose related and 10 g/ml can be attained at a dose of 50 mg/kg, but with an increased risk of patients developing ocular toxicity [16] . The relation between PK and PD parameters (PK/PD index) is considered an important characteristic of drug efficacy [15] . The PK/PD index for EMB according to the above-mentioned C max /MIC data reflects low therapeutic efficacy. Despite this, EMB remains effective even at sub-MICs, as it has a synergistic effect when used with companion drugs [10] . A thorough clinical assessment involving appropriate PK/PD parameters needs to be done to measure the clinical impact of decreased EMB susceptibility in particular on MDR and XDR tuberculosis (TB).
Using MIC values as a microbiological parameter can be misleading, since a critical concentration of 5.0 g/ml in MGIT 960 for EMB is equivalent to 2.0, 2.5, 5.0 and 7.5 g/ml in Löwenstein-Jensen, BACTEC 460, 7H10 and 7H11 media, respectively [4, 10] . Previous studies demonstrated that susceptibility testing of EMB on agarbased medium can lead to underreporting of 50-91% of drug resistance compared with genotypic and radiometric BACTEC 460 testing [2, 8, 9, 13] . Borderline resistance to EMB in clinical isolates was successfully detected in this study by quantitative drug susceptibility testing using MGIT 960 equipped with TB eXiST [14] . This technology is thus recommended to become the standard for susceptibility testing of EMB, given that agar-based critical methods are unreliable.
Fourteen (78%) of 18 isolates with the M306V mutation had MICs 1 12,5 g/ml, which are well above the critical concentration. Only one isolate with this mutation was phenotypic susceptible to EMB with an MIC of 5.0 g/ml (borderline result), while three had moderate levels of resistance (MICs; 1 5.0 to ^ 12.5 g/ml). The M306L mutation was detected in only three isolates with resistance levels similar to those observed in the majority of the M306V mutant isolates (MICs; 1 12.5 to ^ 25.0 g/ml). M306V and M306L were thus associated with higher levels of EMB resistance as opposed to those generated by the M306I substitution. Similar observations were made in previous studies [1-3, 17, 18] , which also implied that M306L is less frequently found in M. tuberculosis strains compared to M306I and M306V. Isolates that acquired either the M306I or M306V mutations had variable EMB MICs within a concentration range of 5.0-50.0 g/ml. However, a fairly high proportion of isolates 43/56 (77%) with the M306I mutation had MICs clustered in a narrow interval ( 1 5 to ^ 12.5 g/ml) adjacent to the critical concentration of 5.0 g/ml. This interval was flanked by 16% (9/56) of the isolates with MICs equivalent to the critical concentration, while 7% (4/56) displayed higher levels of resistance ( 1 12.5 to ^ 25 g/ ml). Similarly, 72% (13/18) of the M306V mutants had MICs of 1 12.5 to ^ 25 g/ml, while 22% (4/13) were below and 6% (1/18) above these concentrations. These data illustrate that the MIC distributions for EMB followed a typical gaussian pattern [7] , suggesting that the majority of the isolates possessed a single mechanism of resistance. The co-existence of other point mutations that were not investigated in this study could be the reason for higher levels of resistance. However, it has previously been shown that single embB mutations are responsible for low to moderate levels of EMB resistance [1, 3, 17, 19] . Based on this assumption, it has been anticipated that two or more independent mutations are needed to mediate high-level EMB resistance in M. tuberculosis [19] . In this study, a high proportion (56/77; 73%) of embB mutants had low to moderate levels of EMB resistance, which is additional evidence that single point mutations are the sole causative reason for resistance. The isolates with MICs above 12.5 g/ml were mainly associated with the M306V and M306L mutations, which are known to mediate higher levels of resistance [1] [2] [3] 18] . Only one of these isolates had an MIC 5-fold higher than the critical concentration. Additional resistance mechanisms or mutations could have been involved [17, 19] in this case, but this study lacks information to confirm or exclude this possibility. Based on the above hypothesis and published evidence [2, 3, 19] , it is unlikely that secondary mutations influenced the susceptibility levels of most of the clinical isolates that were quantified in this study. Decreased susceptibility in 8 isolates that lacked embB 306 mutations points to the presence of sequence alterations elsewhere in the 10-kbp emb CAB operon or in other regions of the genome [1] [2] [3] [4] [17] [18] [19] [20] [21] [22] . Alternative mechanisms or efflux [23] , rather than genetic changes, may also contribute to decreased EMB susceptibility [4, 17, 19, 20] . The mechanisms responsible for EMB resistance are diverse and complex [4, [17] [18] [19] [20] [21] [22] [23] and need further investigation to clarify the actual molecular basis of EMB resistance.
M306I was the most frequently observed mutation (56/77) in this study, followed by M306V (18/77) and then M306L (3/77). M306I was more prevalent in the atypical Beijing (41/77) and LCC (13/77) genotypes and was mainly correlated with a lower level of EMB resistance (5 to ^ 12.5 g/ml). M306V were linked to typical Beijing isolates, while M306L was relatively rare and found in 3 atypical Beijing strains. The Beijing genotype has been associated with younger patients, which reveals a high transmission rate amongst individuals in this age group [24] . Beijing isolates are also frequently associated with MDR TB and serious efforts should therefore be made to prevent its transmission [24] .
Conclusion
Phenotypic and genotypic analyses demonstrated that embB 306 mutations were reliable indicators of EMB susceptibility in a substantial proportion of 111 test isolates. These findings contradict the concept that EMB resistance is a direct consequence of multiple-drug resistance due to embB 306 mutations that predispose isolates to facilitate broad drug resistance [6] . Instead, it is more likely that following the development of drug resistance to the powerful antituberculosis compounds (INH and rifampicin), subpopulations resistant to the less powerful EMB emerge due to increased selective pressure. Subtherapeutic plasma concentrations of INH in patients with a rapid acetylator status could create selective pressure that may lead to treatment failure and the emergence of drug resistance [25] . SNPs at embB 306 displayed diverse MICs of which a significant proportion (73%) was scattered along the critical concentration resulting in borderline resistance. We conclude that borderline resistance can easily be missed by routine phenotypic drug susceptibility testing, hence false-susceptibility reporting. These data have clinical relevance and could be used to improve therapeutic strategies, especially in settings like the Western Cape (South Africa) where drug-resistant TB is problematic.
